On January 17, 2024, Rajeev Shah notified Black Diamond Therapeutics (NASDAQ:BDTX) of his intent to resign from the Company’s Board of Directors (the “Board”), including his position as a member of the Audit Committee of the Board, effective immediately. Mr. Shah served as a member of the Board since December 2018. Mr. Shah’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.